NO335228B1 - Indoleddiksyrederivater og deres anvendelse i behandling og prevensjon av allergisykdommer - Google Patents

Indoleddiksyrederivater og deres anvendelse i behandling og prevensjon av allergisykdommer Download PDF

Info

Publication number
NO335228B1
NO335228B1 NO20061456A NO20061456A NO335228B1 NO 335228 B1 NO335228 B1 NO 335228B1 NO 20061456 A NO20061456 A NO 20061456A NO 20061456 A NO20061456 A NO 20061456A NO 335228 B1 NO335228 B1 NO 335228B1
Authority
NO
Norway
Prior art keywords
methyl
alkyl
acetic acid
indol
fluoro
Prior art date
Application number
NO20061456A
Other languages
English (en)
Norwegian (no)
Other versions
NO20061456L (no
Inventor
Eric Roy Pettipher
Mark Richard Ashton
Edward Andrew Boyd
Frederick Arthur Brookfield
David Middlemiss
Original Assignee
Atopix Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atopix Therapeutics Ltd filed Critical Atopix Therapeutics Ltd
Publication of NO20061456L publication Critical patent/NO20061456L/no
Publication of NO335228B1 publication Critical patent/NO335228B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO20061456A 2003-10-23 2006-03-30 Indoleddiksyrederivater og deres anvendelse i behandling og prevensjon av allergisykdommer NO335228B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0324763.2A GB0324763D0 (en) 2003-10-23 2003-10-23 Use of compounds in therapy
PCT/GB2004/004417 WO2005044260A1 (en) 2003-10-23 2004-10-19 Use of crth2 antagonist compounds in therapy

Publications (2)

Publication Number Publication Date
NO20061456L NO20061456L (no) 2006-07-20
NO335228B1 true NO335228B1 (no) 2014-10-27

Family

ID=29595698

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061456A NO335228B1 (no) 2003-10-23 2006-03-30 Indoleddiksyrederivater og deres anvendelse i behandling og prevensjon av allergisykdommer

Country Status (25)

Country Link
US (5) US7582672B2 (cg-RX-API-DMAC7.html)
EP (2) EP2060258A1 (cg-RX-API-DMAC7.html)
JP (1) JP4313819B2 (cg-RX-API-DMAC7.html)
KR (1) KR20060096145A (cg-RX-API-DMAC7.html)
CN (1) CN101141956B (cg-RX-API-DMAC7.html)
AT (1) ATE439129T1 (cg-RX-API-DMAC7.html)
AU (1) AU2004287245B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0415374B8 (cg-RX-API-DMAC7.html)
CA (1) CA2543199C (cg-RX-API-DMAC7.html)
CY (1) CY1109980T1 (cg-RX-API-DMAC7.html)
DE (1) DE602004022579D1 (cg-RX-API-DMAC7.html)
DK (1) DK1682121T3 (cg-RX-API-DMAC7.html)
ES (1) ES2330113T3 (cg-RX-API-DMAC7.html)
GB (1) GB0324763D0 (cg-RX-API-DMAC7.html)
HR (1) HRP20090577T1 (cg-RX-API-DMAC7.html)
IL (1) IL175085A0 (cg-RX-API-DMAC7.html)
NO (1) NO335228B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ547319A (cg-RX-API-DMAC7.html)
PL (1) PL1682121T3 (cg-RX-API-DMAC7.html)
PT (1) PT1682121E (cg-RX-API-DMAC7.html)
RU (1) RU2412934C2 (cg-RX-API-DMAC7.html)
SI (1) SI1682121T1 (cg-RX-API-DMAC7.html)
UA (1) UA86602C2 (cg-RX-API-DMAC7.html)
WO (1) WO2005044260A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200603235B (cg-RX-API-DMAC7.html)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0301010D0 (sv) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
SA04250253B1 (ar) 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
GB0324763D0 (en) 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
GB0415320D0 (en) 2004-07-08 2004-08-11 Astrazeneca Ab Novel compounds
GB0418830D0 (en) 2004-08-24 2004-09-22 Astrazeneca Ab Novel compounds
US8524715B2 (en) 2004-11-23 2013-09-03 Astrazeneca Ab Phenoxyacetic acid derivatives useful for treating respiratory diseases
BRPI0519280A2 (pt) 2004-12-27 2009-01-06 Actelion Pharmaceuticals Ltd composto, composiÇço farmacÊutica e uso de um composto
GB0504150D0 (en) * 2005-03-01 2005-04-06 Oxagen Ltd Microcrystalline material
GB0505048D0 (en) * 2005-03-11 2005-04-20 Oxagen Ltd Compounds with PGD antagonist activity
GB0512944D0 (en) * 2005-06-24 2005-08-03 Argenta Discovery Ltd Indolizine compounds
JP5064219B2 (ja) 2005-07-22 2012-10-31 塩野義製薬株式会社 Ｐｇｄ２受容体アンタゴニスト活性を有するアザインドール酸誘導体
ES2372701T3 (es) 2005-07-22 2012-01-25 Shionogi & Co., Ltd. Derivado de indol que tiene actividad antagonista del receptor de pgd2.
GB0518783D0 (en) * 2005-09-14 2005-10-26 Argenta Discovery Ltd Indolizine compounds
WO2007044309A2 (en) * 2005-10-05 2007-04-19 Vasix Corporation Device and method for inhibiting age complex formation
WO2007039736A1 (en) 2005-10-06 2007-04-12 Astrazeneca Ab Novel compounds
TW200745003A (en) 2005-10-06 2007-12-16 Astrazeneca Ab Novel compounds
US20080293775A1 (en) * 2005-12-15 2008-11-27 Astrazeneca Ab Substituted Diphenylethers, -Amines, -Sulfides and -Methanes for the Treatment of Respiratory Disease
GB0605743D0 (en) * 2006-03-22 2006-05-03 Oxagen Ltd Salts with CRTH2 antagonist activity
PT2037967T (pt) 2006-06-16 2017-03-14 Univ Pennsylvania Antagonistas do recetor de prostaglandina d2 para o tratamento da alopecia androgenética
EP2492268A1 (en) * 2006-07-22 2012-08-29 Oxagen Limited Compounds having CRTH2 antagonist activity
PT2051962E (pt) 2006-08-07 2012-01-10 Actelion Pharmaceuticals Ltd Derivados do ácido (3-amino-1,2,3,4-tetrahidro-9hcarbazol- 9-il)-acético
EP2094266A1 (en) * 2006-12-21 2009-09-02 Argenta Discovery Limited Crth2 antagonists
WO2008113965A1 (en) * 2007-03-21 2008-09-25 Argenta Discovery Limited Indolizine acetic acid derivatives as crth2 antagonists
AU2008230949B2 (en) * 2007-03-23 2013-05-30 The Board Of Regents Of The University Of Texas System Methods involving aldose reductase inhibitors
EP2129661B1 (en) * 2007-03-29 2012-02-08 Pulmagen Therapeutics (Asthma) Limited Quinoline derivatives as crth2 receptor ligands
UA100983C2 (ru) 2007-07-05 2013-02-25 Астразенека Аб Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты
US8362056B2 (en) 2007-11-05 2013-01-29 Array Biopharma Inc. 4-heteroaryl-substituted phenoxyphenylacetic acid derivatives
GB0722203D0 (en) * 2007-11-13 2007-12-19 Oxagen Ltd Use of CRTH2 antagonist compounds
GB0722216D0 (en) * 2007-11-13 2007-12-27 Oxagen Ltd Use of crth2 antagonist compounds
US20110124683A1 (en) * 2007-11-13 2011-05-26 Oxagen Limited Use of CRTH2 Antagonist Compounds
PL2327693T3 (pl) 2007-12-14 2012-11-30 Pulmagen Therapeutics Asthma Ltd Indole i ich zastosowanie terapeutyczne
RU2503672C2 (ru) 2008-01-18 2014-01-10 Оксаген Лимитед Соединения, обладающие активностью антагонистов crth2
US7750027B2 (en) * 2008-01-18 2010-07-06 Oxagen Limited Compounds having CRTH2 antagonist activity
US20100022613A1 (en) * 2008-01-22 2010-01-28 Oxagen Limited Compounds Having CRTH2 Antagonist Activity
WO2009093029A1 (en) * 2008-01-22 2009-07-30 Oxagen Limited Compounds having crth2 antagonist activity
US8168678B2 (en) 2008-02-01 2012-05-01 Panmira Pharmaceuticals, Inc. N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors
US8242145B2 (en) 2008-02-14 2012-08-14 Panmira Pharmaceuticals, Llc Cyclic diaryl ether compounds as antagonists of prostaglandin D2 receptors
JP2011513242A (ja) 2008-02-25 2011-04-28 アミラ ファーマシューティカルズ，インク． プロスタグランジンｄ２受容体アンタゴニスト
US8426449B2 (en) 2008-04-02 2013-04-23 Panmira Pharmaceuticals, Llc Aminoalkylphenyl antagonists of prostaglandin D2 receptors
EP2300425A4 (en) 2008-06-24 2012-03-21 Panmira Pharmaceuticals Llc PROSTAGLANDIN D2 RECEPTOR CYCLOALCANEÝBINDLUCK ANTAGONISTS
TWI403319B (zh) 2008-07-03 2013-08-01 Panmira Pharmaceuticals Llc 前列腺素ｄ2受體之雜烷基拮抗劑
GB2463788B (en) 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
WO2010039977A2 (en) 2008-10-01 2010-04-08 Amira Pharmaceuticals, Inc. Heteroaryl antagonists of prostaglandin d2 receptors
US8524748B2 (en) 2008-10-08 2013-09-03 Panmira Pharmaceuticals, Llc Heteroalkyl biphenyl antagonists of prostaglandin D2 receptors
GB2465062B (en) 2008-11-06 2011-04-13 Amira Pharmaceuticals Inc Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors
WO2010057118A2 (en) 2008-11-17 2010-05-20 Amira Pharmaceuticals, Inc. Heterocyclic antagonists of prostaglandin d2 receptors
WO2010085820A2 (en) * 2009-01-26 2010-07-29 Amira Pharmaceuticals, Inc. Tricyclic compounds as antagonists of prostaglandin d2 receptors
EP2393492A1 (en) * 2009-02-09 2011-12-14 Boehringer Ingelheim International GmbH New pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
SG177736A1 (en) * 2009-07-31 2012-02-28 Panmira Pharmaceuticals Llc Dermal formulations of dp2 receptor antagonists
JP2013500978A (ja) * 2009-07-31 2013-01-10 パンミラ ファーマシューティカルズ，エルエルシー． Ｄｐ２受容体アンタゴニストの眼の医薬組成物
MX2012001542A (es) 2009-08-05 2012-06-19 Panmira Pharmaceuticals Llc Antagonista dp2 y usos del mismo.
KR20120115989A (ko) 2010-01-06 2012-10-19 판미라 파마슈티칼스, 엘엘씨 Ｄｐ2 길항제 및 이의 용도
PH12012501863A1 (en) 2010-03-22 2021-06-23 Idorsia Pharmaceuticals Ltd 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
US9397745B2 (en) 2010-05-18 2016-07-19 Qualcomm Incorporated Hybrid satellite and mesh network system for aircraft and ship internet service
US8927559B2 (en) 2010-10-11 2015-01-06 Merck Sharp & Dohme Corp. Quinazolinone-type compounds as CRTH2 antagonists
US9469615B2 (en) * 2010-12-23 2016-10-18 Merck Sharp & Dohme Corp. Quinoxalines and AZA-quinoxalines as CRTH2 receptor modulators
GB201103837D0 (en) 2011-03-07 2011-04-20 Oxagen Ltd Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid
UA110245C2 (xx) 2011-04-14 2015-12-10 Actelion Pharmaceuticals Ltd ПОХІДНІ 7-(ГЕТЕРОАРИЛАМІНО)-6,7,8,9-ТЕТРАГІДРОПІРИДО$1,2-а]ІНДОЛ-ОЦТОВОЇ КИСЛОТИ ТА ЇХ ЗАСТОСУВАННЯ ЯК МОДУЛЯТОРІВ РЕЦЕПТОРА ПРОСТАГЛАНДИНУ D2
CN103086943B (zh) * 2011-11-04 2015-04-15 山东亨利医药科技有限责任公司 作为crth2受体拮抗剂的吲哚类衍生物
GB201121557D0 (en) 2011-12-15 2012-01-25 Oxagen Ltd Process
MX2014007239A (es) 2011-12-16 2014-08-08 Atopix Therapeutics Ltd Combinacion de un antagonista crth2 y un inhibidor de bomba de proton para el tratamiento de esofagitis eosinofilica.
JP6186933B2 (ja) * 2013-06-21 2017-08-30 富士通株式会社 接合シート及びその製造方法、並びに放熱機構及びその製造方法
GB201322273D0 (en) * 2013-12-17 2014-01-29 Atopix Therapeutics Ltd Process
SI3119779T1 (sl) 2014-03-17 2018-10-30 Idorsia Pharmaceuticals Ltd Derivati azaindolocetne kisline in njihova uporaba kot modulatorji prostaglandinskega receptorja D2
WO2015140701A1 (en) 2014-03-18 2015-09-24 Actelion Pharmaceuticals Ltd Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators
GB201407820D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
GB201407807D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
TWI695831B (zh) * 2014-09-13 2020-06-11 香港商南北兄弟藥業投資有限公司 Ｃｒｔｈ２拮抗劑化合物及其用途
JP6770522B2 (ja) 2015-02-13 2020-10-14 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 全身性エリテマトーデスを予防し、及び／又は、治療するためのｐｔｇｄｒ−１及び／又はｐｔｇｄｒ−２アンタゴニスト
KR20180033235A (ko) 2015-07-23 2018-04-02 머크 샤프 앤드 돔 코포레이션 Crth2 수용체 길항제에 대한 반응과 연관된 유전자 마커
KR20180031019A (ko) 2015-07-30 2018-03-27 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Ｐｇｄ２에 의한 모발 성장 억제에 대한 민감성의 검출을 위한 인간 ｄｐ―２ 유전자의 단일 뉴클레오티드 다형성 대립유전자
ES2867757T3 (es) 2015-09-15 2021-10-20 Idorsia Pharmaceuticals Ltd Formas cristalinas
AU2017298256B2 (en) * 2016-07-21 2020-11-26 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Indole derivative used as CRTH2 inhibitor
CN109563093B (zh) 2016-07-21 2021-09-03 正大天晴药业集团股份有限公司 作为crth2抑制剂的三并环类化合物
CN108101829B (zh) * 2017-11-19 2020-05-12 华南理工大学 一种吲哚化合物、其制备方法及应用
CA3088917A1 (en) 2018-01-19 2019-07-25 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Crystal form of indole derivative and preparation method and use thereof
WO2020136095A1 (en) 2018-12-27 2020-07-02 Chiesi Farmaceutici S.P.A. Pharmaceutical composition comprising spherical agglomerates of timapiprant
CN115745864B (zh) * 2021-09-03 2025-10-10 深圳零一生命科技有限责任公司 吲哚类化合物及其制备方法和应用

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4324418Y1 (cg-RX-API-DMAC7.html) 1965-04-06 1968-10-15
US3489767A (en) * 1966-01-12 1970-01-13 Sumitomo Chemical Co 1-(phenylsulfonyl)-3-indolyl aliphatic acid derivatives
US3557142A (en) 1968-02-20 1971-01-19 Sterling Drug Inc 4,5,6,7-tetrahydro-indole-lower-alkanoic acids and esters
US3577142A (en) * 1969-02-28 1971-05-04 Westinghouse Learning Corp Code translation system
BE790679A (fr) 1971-11-03 1973-04-27 Ici Ltd Derives de l'indole
GB1407658A (en) 1973-03-06 1975-09-24 Ici Ltd Process for the manufacture of indole derivatives
GB1460348A (en) 1974-02-04 1977-01-06 Ici Ltd Quinazoline derivativesa
DK151884C (da) * 1979-03-07 1988-06-13 Pfizer Analogifremgangsmaade til fremstilling af 3-(1-imidazolylalkyl)indolderivater eller farmaceutisk acceptable syreadditionssalte deraf
US4363912A (en) * 1980-12-15 1982-12-14 Pfizer Inc. Indole thromboxane synthetase inhibitors
US4966911A (en) * 1984-11-20 1990-10-30 Washington Research Foundation Immunoregulatory agents
GB8607294D0 (en) * 1985-04-17 1986-04-30 Ici America Inc Heterocyclic amide derivatives
WO1993012786A1 (en) 1986-07-10 1993-07-08 Howard Harry R Jr Indolinone derivatives
US5236945A (en) * 1990-06-11 1993-08-17 Pfizer Inc. 1H-indazole-3-acetic acids as aldose reductase inhibitors
GB9122590D0 (en) * 1991-10-24 1991-12-04 Lilly Industries Ltd Pharmaceutical compounds
US5612360A (en) * 1992-06-03 1997-03-18 Eli Lilly And Company Angiotensin II antagonists
GB9317764D0 (en) 1993-08-26 1993-10-13 Pfizer Ltd Therapeutic compound
JP3228381B2 (ja) * 1993-10-29 2001-11-12 ソニー株式会社 Ａｖセレクタ
US5641800A (en) 1994-07-21 1997-06-24 Eli Lilly And Company 1H-indole-1-functional sPLA2 inhibitors
IL117208A0 (en) 1995-02-23 1996-06-18 Nissan Chemical Ind Ltd Indole type thiazolidines
PL185107B1 (pl) * 1995-06-21 2003-02-28 Shionogi & Co Bicykliczne związki aminowe, kompozycja farmaceutyczna i jej stosowanie
WO1997046677A1 (fr) 1996-06-05 1997-12-11 Bml, Inc. PROTEINE SPECIFIQUE DU Th2 HUMAIN, GENE (B19) CODANT POUR CETTE PROTEINE, TRANSFORMANT, VECTEUR DE RECOMBINAISON ET ANTICORPS MONOCLONAL S'Y RAPPORTANT
KR20010041343A (ko) 1998-02-25 2001-05-15 브루스 엠. 에이센, 토마스 제이 데스로저 포스포리파제 효소의 억제제
US6916841B2 (en) 1998-02-25 2005-07-12 Genetics Institute, Llc Inhibitors of phospholipase enzymes
AU774929B2 (en) * 1998-03-31 2004-07-15 Institutes For Pharmaceutical Discovery, Llc, The Substituted indolealkanoic acids
GB9825524D0 (en) * 1998-11-20 1999-01-13 Oxford Biomedica Ltd Vector
TNSN99224A1 (fr) * 1998-12-01 2005-11-10 Inst For Pharm Discovery Inc Methodes de reduction des niveaux de glucose et triglyceride en serum et pour suppression de l'antigenese utilisant les acides la indolealkanoique
WO2001014882A1 (fr) 1999-08-23 2001-03-01 Bml, Inc. Identification des proprietes d'une substance pour les recepteurs de prostaglandine d
EP1166011A1 (en) 2000-01-14 2002-01-02 Koninklijke Philips Electronics N.V. Display device
WO2001051489A2 (en) * 2000-01-14 2001-07-19 The Institutes For Pharmaceutical Discovery, Llc Methods for lowering uric acid levels
US6521659B2 (en) * 2000-03-02 2003-02-18 Institute For Pharmaceutical Discovery, Llc Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor
JP2001247570A (ja) 2000-03-08 2001-09-11 Japan Tobacco Inc インドール酢酸化合物及びその製造方法
US6878522B2 (en) * 2000-07-07 2005-04-12 Baiyong Li Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
SE0200356D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
SE0200411D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
JP4484108B2 (ja) 2002-05-16 2010-06-16 塩野義製薬株式会社 Ｐｇｄ２受容体拮抗作用を有する化合物
AU2003231513A1 (en) 2002-05-16 2003-12-02 Shionogi And Co., Ltd. Pgd2 receptor antagonist
TW200307542A (en) 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
US7364647B2 (en) 2002-07-17 2008-04-29 Eksigent Technologies Llc Laminated flow device
MXPA05006282A (es) * 2002-12-10 2005-08-19 Wyeth Corp Derivados del acido 1h-indol-1-il acetico de 3-alquilo y 3-arilalquilo sustituido como inhibidores del inhibidor-1 de activador de plasminogeno (pai-1).
EP1585511B1 (en) 2002-12-20 2013-01-23 Amgen Inc. Asthma and allergic inflammation modulators
JP4324418B2 (ja) 2003-08-05 2009-09-02 株式会社日立国際電気 基板処理装置および半導体デバイスの製造方法
EP1675826A1 (en) * 2003-10-14 2006-07-05 Oxagen Limited Compounds having crth2 antagonist activity
GB0324763D0 (en) 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
GB0504150D0 (en) 2005-03-01 2005-04-06 Oxagen Ltd Microcrystalline material
GB0505048D0 (en) 2005-03-11 2005-04-20 Oxagen Ltd Compounds with PGD antagonist activity
US20090181139A1 (en) * 2005-04-12 2009-07-16 Mohammed Mehid Farid Pressure Assisted Thermal Sterilisation or Pasteurisation Method and Apparatus
PL65781Y1 (pl) 2005-08-16 2012-02-29 Katarzyna Kawczyńska Wkładka kosmetyczna
GB0605743D0 (en) 2006-03-22 2006-05-03 Oxagen Ltd Salts with CRTH2 antagonist activity
EP2492268A1 (en) 2006-07-22 2012-08-29 Oxagen Limited Compounds having CRTH2 antagonist activity
US20110124683A1 (en) 2007-11-13 2011-05-26 Oxagen Limited Use of CRTH2 Antagonist Compounds
US7750027B2 (en) 2008-01-18 2010-07-06 Oxagen Limited Compounds having CRTH2 antagonist activity
RU2503672C2 (ru) 2008-01-18 2014-01-10 Оксаген Лимитед Соединения, обладающие активностью антагонистов crth2
WO2009093029A1 (en) 2008-01-22 2009-07-30 Oxagen Limited Compounds having crth2 antagonist activity
US20100022613A1 (en) 2008-01-22 2010-01-28 Oxagen Limited Compounds Having CRTH2 Antagonist Activity

Also Published As

Publication number Publication date
CN101141956A (zh) 2008-03-12
ATE439129T1 (de) 2009-08-15
ZA200603235B (en) 2009-03-25
NO20061456L (no) 2006-07-20
AU2004287245B2 (en) 2009-03-26
CN101141956B (zh) 2011-04-20
HK1093435A1 (en) 2007-03-02
GB0324763D0 (en) 2003-11-26
EP2060258A1 (en) 2009-05-20
JP2007509114A (ja) 2007-04-12
NZ547319A (en) 2009-03-31
US8314257B2 (en) 2012-11-20
EP1682121B1 (en) 2009-08-12
RU2006109769A (ru) 2007-11-27
AU2004287245A1 (en) 2005-05-19
JP4313819B2 (ja) 2009-08-12
DK1682121T3 (da) 2009-10-26
UA86602C2 (ru) 2009-05-12
US8163931B2 (en) 2012-04-24
EP1682121A1 (en) 2006-07-26
HRP20090577T8 (en) 2009-12-31
CY1109980T1 (el) 2014-09-10
US7582672B2 (en) 2009-09-01
CA2543199C (en) 2014-09-23
PT1682121E (pt) 2009-11-03
US8198314B2 (en) 2012-06-12
US20050119268A1 (en) 2005-06-02
BRPI0415374B1 (pt) 2018-10-09
HRP20090577T1 (hr) 2009-12-31
DE602004022579D1 (de) 2009-09-24
KR20060096145A (ko) 2006-09-07
SI1682121T1 (sl) 2010-01-29
US20090018139A1 (en) 2009-01-15
US8163936B2 (en) 2012-04-24
IL175085A0 (en) 2008-04-13
US20090018138A1 (en) 2009-01-15
US20090023788A1 (en) 2009-01-22
PL1682121T3 (pl) 2010-01-29
BRPI0415374B8 (pt) 2021-05-25
CA2543199A1 (en) 2005-05-19
US20090018338A1 (en) 2009-01-15
WO2005044260A1 (en) 2005-05-19
ES2330113T3 (es) 2009-12-04
BRPI0415374A (pt) 2006-12-12
RU2412934C2 (ru) 2011-02-27

Similar Documents

Publication Publication Date Title
NO335228B1 (no) Indoleddiksyrederivater og deres anvendelse i behandling og prevensjon av allergisykdommer
US8044088B2 (en) 1-acetic acid-indole derivatives with PGD2 antagonist activity
US20070232681A1 (en) Compounds Having Crth2 Antagonist Activity
NZ587251A (en) Indole derivatives having CRTH2 antagonist activity
GB2407318A (en) Substituted Indol-3-yl acetic acid derivatives
WO2005121141A1 (en) Pyrrolopyridine derivatives and use thereof for treating diseases mediated by prostaglandin d2 (pgd2)
MXPA06004506A (en) Use of crth2 antagonist compounds in therapy
HK1093435B (en) Use of crth2 antagonist compounds in therapy
HK1109628B (en) 1-acetic acid-indole derivatives with pgd2 antagonist activity

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: ATOPIX THERAPEUTICS LTD, GB

MM1K Lapsed by not paying the annual fees